Argenx SE Reports Robust Q2 2026 Performance, Catalyzed by Vyvgart
Argenx SE (NYSE: ARGX; Euronext Brussels: ARGNF) announced its second‑quarter 2026 results on July 23, 2026, delivering a striking 60 % increase in sales year‑over‑year. The growth was almost entirely driven by the antibody‑based therapy Vyvgart (emphasis on muscular weakness), which now accounts for the majority of the company’s revenue. Revenue reached US$1.52 billion, surpassing expectations by US$90 million, while the GAAP earnings‑per‑share (EPS) of $7.32 exceeded forecasts by $1.12.
Vyvgart Fuels the Surge
The company highlighted that Vyvgart’s sales jumped from $1.84 billion in the first half of 2025 to $2.9 billion in the first six months of 2026. This surge translates to a 60 % YoY increase, reflecting the drug’s strong uptake among patients with myasthenia gravis and other neuromuscular disorders. Analysts note that the drug’s revenue contribution has grown from a modest fraction to a near‑single‑source driver, underscoring Vyvgart’s centrality to Argenx’s commercial strategy.
Pipeline Readouts on the Horizon
While Vyvgart dominates current sales, Argenx has multiple pipeline candidates poised for upcoming readouts, notably Empasiprubart and VYVGART (a second indication of Vyvgart). The company expects several clinical milestones in the coming months, which could broaden its revenue base and reinforce its position in the immunology market. The earnings call emphasized that these forthcoming readouts are anticipated to further bolster the company’s growth trajectory.
Investor Sentiment and Valuation
Following the announcement, market participants reacted positively, with the share price climbing from €758.4 at close on July 21 to €833.6 earlier this week, approaching the 52‑week high. Despite this upside, Citizens, a prominent equity research firm, reduced its target price to $932 on July 24, citing a reassessment of the company’s valuation multiples amid the growing concentration of sales in a single product. The revised target reflects a price‑earnings ratio of 38.4, aligning with the sector’s premium valuations but acknowledging potential upside risks.
Financial Position
Argenx’s market capitalization stands at €51.49 billion, underscoring its status as a leading biopharmaceutical entity within the European healthcare sector. Operating on a strong revenue base and a robust pipeline, the company continues to invest in research and development while maintaining a disciplined cost structure, positioning it favorably for sustained growth.
Outlook
Argenx’s management reiterated confidence in its commercial strategy, stressing that the company’s pipeline, coupled with Vyvgart’s performance, will underpin continued revenue expansion. The forthcoming pipeline readouts are expected to diversify revenue streams, potentially reducing reliance on a single therapy and supporting the company’s long‑term valuation.
This article synthesizes publicly released financial data and market commentary as of July 24, 2026. All figures are reported in the company’s statement of financial performance and subsequent analyst coverage.
